Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study.

Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, Wood K, Holmberg SD, Brooks JT; HIV Outpatient Study (HOPS) Investigators.

Clin Infect Dis. 2010 Aug 15;51(4):435-47. doi: 10.1086/655144.

2.

Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study.

Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, van Lunzen J, Antunes F, Phillips AN, Lundgren JD.

Ann Intern Med. 1999 Apr 6;130(7):570-7.

PMID:
10189326
3.

Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M; Swiss HIV Cohort Study.

Clin Infect Dis. 2005 Aug 1;41(3):361-72. Epub 2005 Jun 24.

4.

Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.

Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G; Italian MASTER Cohort.

Antivir Ther. 2007;12(6):941-7.

PMID:
17926648
5.

Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study.

Sogaard OS, Lohse N, Gerstoft J, Kronborg G, Ostergaard L, Pedersen C, Pedersen G, Sørensen HT, Obel N.

Clin Infect Dis. 2008 Nov 15;47(10):1345-53. doi: 10.1086/592692.

6.

Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy.

Sparano JA, Hu X, Wiernik PH, Sarta C, Reddy DM, Hanau L, Henry DH.

J Natl Cancer Inst. 1997 Feb 19;89(4):301-7.

8.

Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa.

Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepelman AI, Manabe YC.

PLoS One. 2010 May 7;5(5):e10527. doi: 10.1371/journal.pone.0010527.

9.

Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events.

Albert MA, Glynn RJ, Buring J, Ridker PM.

Circulation. 2006 Dec 12;114(24):2619-26. Epub 2006 Nov 20.

10.
11.

CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.

Seminari E, De Silvestri A, Boschi A, Tinelli C.

AIDS Rev. 2008 Oct-Dec;10(4):236-44.

PMID:
19092979
12.

Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.

Wannamethee SG, Sirivichayakul S, Phillips AN, Ubolyam S, Ruxrungtham K, Hanvanich M, Phanuphak P.

Int J Epidemiol. 1998 Apr;27(2):289-95.

13.

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.

Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group.

AIDS. 2003 May 23;17(8):1179-93.

PMID:
12819520
14.

Daytime sleepiness predicts mortality and cardiovascular disease in older adults. The Cardiovascular Health Study Research Group.

Newman AB, Spiekerman CF, Enright P, Lefkowitz D, Manolio T, Reynolds CF, Robbins J.

J Am Geriatr Soc. 2000 Feb;48(2):115-23.

PMID:
10682939
15.

Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.

Khanna N, Elzi L, Mueller NJ, Garzoni C, Cavassini M, Fux CA, Vernazza P, Bernasconi E, Battegay M, Hirsch HH; Swiss HIV Cohort Study.

Clin Infect Dis. 2009 May 15;48(10):1459-66. doi: 10.1086/598335.

16.

Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.

Martín-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobí F, Alegre M, Goyenechea A, Pedreira J, González del Castillo J, Martínez-Lacasa J, Ocampo A, Alsina M, Santos J, Podzamczer D, González-Lahoz J; Caelyx/Kaposi's Sarcoma Spanish Group.

Clin Infect Dis. 2008 Aug 1;47(3):410-7. doi: 10.1086/589865.

17.

Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

Chêne G, Binquet C, Moreau JF, Neau D, Pellegrin I, Malvy D, Ceccaldi J, Lacoste D, Dabis F.

AIDS. 1998 Dec 3;12(17):2313-20.

PMID:
9863874
18.
19.

Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte Ad, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD.

Arch Intern Med. 2006 Aug 14-28;166(15):1632-41.

PMID:
16908797
20.

Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage GR 3rd; Pediatric AIDS Clincial Trials Group Protocol 219C Team.

Arch Pediatr Adolesc Med. 2006 Aug;160(8):778-87.

PMID:
16894075
Items per page

Supplemental Content

Write to the Help Desk